ClinicalTrials.gg
Active, not recruitingNCT06465329Updated Nov 3, 2026

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Cemiplimab and Platinum-based chemotherapy in Non Small Cell Lung Cancer and NSCLC, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Planned enrollment
6th of 18
184 · median 86
Started
2024
with 2 others
Phase 2
7 of 21
1 open now
Primary completion
2029-12
later than 7 of 10 live
Registered
19th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion.

The aim of the resectable NSCLC portion is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug.

For each investigational arm, the available data will be reviewed to decide whether safety testing with chemotherapy is needed before moving the treatment combination to the main resectable NSCLC portion of the study. If safety testing with chemotherapy is required, adult participants whose tumour has spread to other organs or cannot be removed by surgery, will be enrolled in the unresectable/metastatic NSCLC portion of the study called the "safety lead-in."

The aim of the unresectable/metastatic NSCLC safety lead-in portion is to evaluate the safety of the combination of Cemiplimab, chemotherapy, and an additional drug in participants with unresectable or metastatic NSCLC.

For the resectable NSCLC portion, the study is also looking at several other research questions, including:

  • What are the side effects associated with the investigational treatments in comparison to the control treatment
  • Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed
  • How much of the study drug(s) are in the blood at a given time
  • Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)

For the unresectable/metastatic NSCLC portion, the study is also looking at several other research questions, including:

  • What are the side effects associated with the additional drug in combination with cemiplimab and chemotherapy
  • How does the additional drug work in combination with cemiplimab and chemotherapy
03

Conditions studied

  • Non Small Cell Lung Cancer
  • NSCLC

Keywords

  • Carcinoma, Non-Small Cell Lung
  • Early stage lung cancer
  • Early-stage non-small cell lung cancer
  • Lung cancer surgery
  • Lung Carcinoma
  • Neoadjuvant NSCLC
  • Non-small cell lung carcinoma
  • NSCLC
  • Operable non-small cell lung cancer
  • Preoperative NSCLC
  • Resectable NSCLC
  • Surgical resection
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Resectable NSCLC General Key Inclusion Criteria:

  1. confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol
  2. per (RECIST) criteria version 1.1
  3. Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol
  4. Performance Status scale (ECOG PS) of 0 to 1
  5. Adequate organ and bone marrow function, as described in the protocol

Arm Specific Inclusion Criteria:

Unresectable/ NSCLC Safety Lead-in - Arm 2:

  1. Non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC
  2. Availability of an archival or on-trial FFPE tumor tissue sample
  3. ECOG performance status of 0 or 1
  4. Per investigator judgment, of at least 3 months

Neoadjuvant Resectable NSCLC General Key Exclusion Criteria:

  1. Any systemic anti-cancer therapy or radiotherapy for the current tumor, as described in the protocol
  2. Presence of actionable oncogenic alterations in the tumor for which an approved targeted therapy is available or for which perioperative chemoimmunotherapy is not considered an appropriate standard of care treatment, as described in the protocol
  3. Presence of grade≥ 2 peripheral neuropathy
  4. Another that is progressing or requires active treatment, as described in the protocol

Arm Specific Exclusion Criteria:

Neoadjuvant Resectable NSCLC - Arm 1:

  1. Grade ≥3 hypercalcemia, as defined in the protocol
  2. Any central nervous system (CNS) pathology that could increase the risk of immune effector cell-associated neurotoxicity syndrome (ICANS), as described in the protocol
  3. Has marked baseline prolongation of the time from the start of the Q wave to the end of the T wave in ()/corrected QT interval (QTc) interval or risk factors for prolonged QTc, as described in the protocol

Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2:

  1. Untreated or active primary brain tumor, , , or spinal cord compression, as described in the protocol
  2. Presence of actionable oncogenic alterations in the tumor for which a chemotherapy plus programmed cell death protein 1 (PD1) inhibitor backbone is not the appropriate initial therapy as standard of care
  3. Known allergy or to any components of trial interventions
  4. Any condition requiring ongoing/continuous therapy, as described in the protocol

Neoadjuvant Resectable NSCLC - Arm 2:

1. History of encephalitis, meningitis, organic brain disease, or uncontrolled seizures within 1 year prior to the first dose of trial interventions.

Note: Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Active comparator
    Neoadjuvant Resectable NSCLC - Control Arm

    Drug: Cemiplimab · Drug: Platinum-based chemotherapy

  • Experimental
    Neoadjuvant Resectable NSCLC - Arm 1

    Drug: Cemiplimab · Drug: Platinum-based chemotherapy · Drug: Marlotamig

  • Experimental
    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Drug: Cemiplimab · Drug: Platinum-based chemotherapy · Drug: REGN10597

  • Experimental
    Neoadjuvant Resectable NSCLC - Arm 2

    Drug: Cemiplimab · Drug: Platinum-based chemotherapy · Drug: REGN10597

Interventions

  • Administered per the protocol

    Also known as: REGN2810, LIBTAYO

  • DrugPlatinum-based chemotherapy

    Administered per the protocol

  • DrugMarlotamig

    Administered per the protocol

    Also known as: REGN7075

  • DrugREGN10597

    Administered per the protocol

    Also known as: PD-1-IL2Ra-IL2 immunotherapy

06

What researchers measure

Primary outcomes

  1. Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR)

    Time frame: Up to 12 weeks

  2. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 9 weeks

  3. Occurrence of TEAEs leading to death

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 9 weeks

  4. Occurrence of TEAEs leading to treatment discontinuation

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 9 weeks

  5. Occurrence of Serious Adverse Events (SAEs)

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 9 weeks

  6. Occurrence of grade ≥3 laboratory abnormalities

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2 As assessed by the Common Terminology Criteria for Adverse Events (CTCAE) grading system version 5.0 (for all grades)

    Time frame: Up to 9 weeks

  7. Number of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cycles

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 9 weeks

Secondary outcomes

  1. Pathologic Complete Response (pCR) rate as determined by central BIPR

    Time frame: Up to 12 weeks

  2. Residual Viable Tumor (RVT) as determined by central BIPR

    Time frame: Up to 12 weeks

  3. Event-Free Survival (EFS)

    Time frame: Up to 5 years

  4. Objective Response by investigator assessment

    Time frame: Up to 9 weeks

  5. Duration of Response (DoR) by investigator assessment

    Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2

    Time frame: Up to 2 years

  6. Overall Survival (OS)

    Time frame: Up to 5 years

  7. Occurrence of TEAEs

    Time frame: Up to 76 weeks

  8. Severity of TEAEs

    Time frame: Up to 76 weeks

  9. Occurrence of TEAEs leading to death

    Time frame: Up to 76 weeks

  10. Occurrence of TEAEs leading to treatment discontinuation

    Time frame: Up to 76 weeks

  11. Occurrence of SAEs

    Time frame: Up to 76 weeks

  12. Severity of SAEs

    Time frame: Up to 76 weeks

  13. Occurrence of Adverse Events of Special Interest (AESIs)

    Time frame: Up to 76 weeks

  14. Severity of AESIs

    Time frame: Up to 76 weeks

  15. Occurrence of immune-mediated Adverse Events (imAEs)

    Time frame: Up to 76 weeks

  16. Severity of imAEs

    Time frame: Up to 76 weeks

  17. Occurrence of Infusion-Related Reactions (IRRs)

    Time frame: Up to 76 weeks

  18. Severity of IRRs

    Time frame: Up to 76 weeks

  19. Occurrence of grade ≥3 laboratory abnormalities

    As assessed by the Common Terminology Criteria for Adverse Events (CTCAE) grading system version 5.0 (for all grades)

    Time frame: Up to 76 weeks

  20. Proportion of delayed surgeries due to TEAEs

    Time frame: Up to 76 weeks

  21. Proportion of cancelled surgeries due to TEAEs

    Time frame: Up to 76 weeks

  22. Occurrence of Anti-Drug Antibodies (ADAs) to cemiplimab

    Time frame: Up to 67 weeks

  23. Magnitude of ADAs to cemiplimab

    Time frame: Up to 67 weeks

  24. Occurrence of ADAs to marlotamig

    Time frame: Up to 67 weeks

  25. Magnitude of ADAs to marlotamig

    Time frame: Up to 67 weeks

  26. Occurrence of ADAs to REGN10597

    Time frame: Up to 67 weeks

  27. Magnitude of ADAs to REGN10597

    Time frame: Up to 67 weeks

07

Study locations

47 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 60 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion May 2027 → Dec 2029 and completion May 2030 → Dec 2034.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 18, 2024
StartActual
Nov 18, 2024
Primary completionEst.
Dec 4, 2029was May 2027
CompletionEst.
Dec 27, 2034was May 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 20, 2027→Dec 4, 2029
Nov 3, 2026
Study completion
May 2, 2030→Dec 27, 2034
Nov 3, 2026
Enrollment
120→184
Nov 3, 2026
Eligibility
4 criteria edited, 13 added
What changed in the criteria
  • EditedNeoadjuvant Resectable NSCLC General Key Inclusion Criteria:
  • AddedArm Specific Inclusion Criteria:
  • AddedUnresectable/Metastatic NSCLC Safety Lead-in - Arm 2:
  • AddedNon-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC
  • AddedAvailability of an archival or on-trial FFPE tumor tissue sample
  • AddedECOG performance status of 0 or 1
  • AddedPer investigator judgment, life expectancy of at least 3 months
  • EditedNeoadjuvant Resectable NSCLC General Key Exclusion Criteria:
  • ChangedBefore Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocolNow Presence of actionable oncogenic alterations in the tumor for which an approved targeted therapy is available or for which perioperative chemoimmunotherapy is not considered an appropriate standard of care treatment, as described in the protocol
  • EditedNeoadjuvant Resectable NSCLC - Arm 1:
  • AddedUnresectable/Metastatic NSCLC Safety Lead-in - Arm 2:
  • AddedUntreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression, as described in the protocol
  • AddedPresence of actionable oncogenic alterations in the tumor for which a chemotherapy plus programmed cell death protein 1 (PD1) inhibitor backbone is not the appropriate initial therapy as standard of care
  • AddedKnown allergy or hypersensitivity to any components of trial interventions
  • AddedAny condition requiring ongoing/continuous corticosteroid therapy, as described in the protocol
  • AddedNeoadjuvant Resectable NSCLC - Arm 2:
  • Added1. History of encephalitis, meningitis, organic brain disease, or uncontrolled seizures within 1 year prior to the first dose of trial interventions.
Nov 3, 2026
Interventions
Changed REGN7075→Marlotamig. Added Drug: REGN10597. Arms added: Neoadjuvant Resectable NSCLC - Control Arm·Neoadjuvant Resectable NSCLC - Arm 1·Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2·Neoadjuvant Resectable NSCLC - Arm 2; arms removed: Chemotherapy+Cemiplimab·Arm 1: Chemotherapy+Cemiplimab+REGN7075
Nov 3, 2026
Primary outcomes
1 edited, 6 added
What changed in the outcomes
  • EditedMajor pathologic responsePathologic Response (MPR) rate as determined by central blinded independent pathology reviewBlinded Independent Pathology Review (BIPR)Time frame: Up to 12 weeks
  • AddedOccurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 9 weeks
  • AddedOccurrence of TEAEs leading to deathTime frame: Up to 9 weeks
  • AddedOccurrence of TEAEs leading to treatment discontinuationTime frame: Up to 9 weeks
  • AddedOccurrence of Serious Adverse Events (SAEs)Time frame: Up to 9 weeks
  • AddedOccurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 9 weeks
  • AddedNumber of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cyclesTime frame: Up to 9 weeks
Nov 3, 2026
Secondary outcomes
12 edited, 12 added, 6 removed
What changed in the outcomes
  • EditedPathologic complete responseComplete Response (pCR) rate as determined by central BIPRTime frame: Up to 12 weeks
  • EditedResidual viable tumorViable Tumor (RVT) as determined by central BIPRTime frame: Up to 12 weeks
  • EditedMedian event-free survivalEvent-Free Survival (EFS)Time frame: Up to 5 years
  • EditedOverall survivalSurvival (OS)Time frame: Up to 5 years
  • EditedIncidenceOccurrence of treatment-emergent adverse eventsAdverse Events of Special Interest (TEAEsAESIs)Time frame: Up to 76 weeks
  • EditedIncidenceOccurrence of TEAEs leading to deathTime frame: Up to 76 weeks
  • EditedIncidenceOccurrence of TEAEs leading to treatment discontinuationTime frame: Up to 76 weeks
  • EditedIncidenceOccurrence of serious adverse eventsimmune-mediated Adverse Events (SAEsimAEs)Time frame: Up to 76 weeks
  • EditedIncidenceOccurrence of infusionInfusion-related reactionsRelated Reactions (IRRs)Time frame: Up to 76 weeks
  • EditedIncidenceOccurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 76 weeks
  • EditedIncidenceOccurrence of antiAnti-drug antibodiesDrug Antibodies (ADAs) to cemiplimab over timeTime frame: Up to 67 weeks
  • EditedTiterMagnitude of ADAs to cemiplimab over timeTime frame: Up to 67 weeks
  • AddedObjective Response by investigator assessmentTime frame: Up to 9 weeks
  • AddedDuration of Response (DoR) by investigator assessmentTime frame: Up to 2 years
  • AddedOccurrence of TEAEsTime frame: Up to 76 weeks
  • AddedOccurrence of SAEsTime frame: Up to 76 weeks
  • AddedSeverity of SAEsTime frame: Up to 76 weeks
  • AddedSeverity of AESIsTime frame: Up to 76 weeks
  • AddedSeverity of imAEsTime frame: Up to 76 weeks
  • AddedSeverity of IRRsTime frame: Up to 76 weeks
  • AddedOccurrence of ADAs to marlotamigTime frame: Up to 67 weeks
  • AddedMagnitude of ADAs to marlotamigTime frame: Up to 67 weeks
  • AddedOccurrence of ADAs to REGN10597Time frame: Up to 67 weeks
  • AddedMagnitude of ADAs to REGN10597Time frame: Up to 67 weeks
  • RemovedEFS rateTime frame: Up to 5 years
  • RemovedObjective response rate (ORR)Time frame: Up to 9 weeks
  • RemovedIncidence of adverse events of special interest (AESIs)Time frame: Up to 76 weeks
  • RemovedIncidence of immune-mediated adverse events (imAEs)Time frame: Up to 76 weeks
  • RemovedIncidence of ADAs to novel anti-cancer agents over timeTime frame: Up to 67 weeks
  • RemovedTiter of ADAs to novel anti-cancer agents over timeTime frame: Up to 67 weeks
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion May 20, 2027→Dec 4, 2029
    Study completion May 2, 2030→Dec 27, 2034
    Enrollment 120→184
    Eligibility 4 criteria edited, 13 added
    What changed in the criteria
    • EditedNeoadjuvant Resectable NSCLC General Key Inclusion Criteria:
    • AddedArm Specific Inclusion Criteria:
    • AddedUnresectable/Metastatic NSCLC Safety Lead-in - Arm 2:
    • AddedNon-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC
    • AddedAvailability of an archival or on-trial FFPE tumor tissue sample
    • AddedECOG performance status of 0 or 1
    • AddedPer investigator judgment, life expectancy of at least 3 months
    • EditedNeoadjuvant Resectable NSCLC General Key Exclusion Criteria:
    • ChangedBefore Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocolNow Presence of actionable oncogenic alterations in the tumor for which an approved targeted therapy is available or for which perioperative chemoimmunotherapy is not considered an appropriate standard of care treatment, as described in the protocol
    • EditedNeoadjuvant Resectable NSCLC - Arm 1:
    • AddedUnresectable/Metastatic NSCLC Safety Lead-in - Arm 2:
    • AddedUntreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression, as described in the protocol
    • AddedPresence of actionable oncogenic alterations in the tumor for which a chemotherapy plus programmed cell death protein 1 (PD1) inhibitor backbone is not the appropriate initial therapy as standard of care
    • AddedKnown allergy or hypersensitivity to any components of trial interventions
    • AddedAny condition requiring ongoing/continuous corticosteroid therapy, as described in the protocol
    • AddedNeoadjuvant Resectable NSCLC - Arm 2:
    • Added1. History of encephalitis, meningitis, organic brain disease, or uncontrolled seizures within 1 year prior to the first dose of trial interventions.
    Primary outcomes 1 edited, 6 added
    What changed in the outcomes
    • EditedMajor pathologic responsePathologic Response (MPR) rate as determined by central blinded independent pathology reviewBlinded Independent Pathology Review (BIPR)Time frame: Up to 12 weeks
    • AddedOccurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 9 weeks
    • AddedOccurrence of TEAEs leading to deathTime frame: Up to 9 weeks
    • AddedOccurrence of TEAEs leading to treatment discontinuationTime frame: Up to 9 weeks
    • AddedOccurrence of Serious Adverse Events (SAEs)Time frame: Up to 9 weeks
    • AddedOccurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 9 weeks
    • AddedNumber of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cyclesTime frame: Up to 9 weeks
    Secondary outcomes 12 edited, 12 added, 6 removed
    What changed in the outcomes
    • EditedPathologic complete responseComplete Response (pCR) rate as determined by central BIPRTime frame: Up to 12 weeks
    • EditedResidual viable tumorViable Tumor (RVT) as determined by central BIPRTime frame: Up to 12 weeks
    • EditedMedian event-free survivalEvent-Free Survival (EFS)Time frame: Up to 5 years
    • EditedOverall survivalSurvival (OS)Time frame: Up to 5 years
    • EditedIncidenceOccurrence of treatment-emergent adverse eventsAdverse Events of Special Interest (TEAEsAESIs)Time frame: Up to 76 weeks
    • EditedIncidenceOccurrence of TEAEs leading to deathTime frame: Up to 76 weeks
    • EditedIncidenceOccurrence of TEAEs leading to treatment discontinuationTime frame: Up to 76 weeks
    • EditedIncidenceOccurrence of serious adverse eventsimmune-mediated Adverse Events (SAEsimAEs)Time frame: Up to 76 weeks
    • EditedIncidenceOccurrence of infusionInfusion-related reactionsRelated Reactions (IRRs)Time frame: Up to 76 weeks
    • EditedIncidenceOccurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 76 weeks
    • EditedIncidenceOccurrence of antiAnti-drug antibodiesDrug Antibodies (ADAs) to cemiplimab over timeTime frame: Up to 67 weeks
    • EditedTiterMagnitude of ADAs to cemiplimab over timeTime frame: Up to 67 weeks
    • AddedObjective Response by investigator assessmentTime frame: Up to 9 weeks
    • AddedDuration of Response (DoR) by investigator assessmentTime frame: Up to 2 years
    • AddedOccurrence of TEAEsTime frame: Up to 76 weeks
    • AddedOccurrence of SAEsTime frame: Up to 76 weeks
    • AddedSeverity of SAEsTime frame: Up to 76 weeks
    • AddedSeverity of AESIsTime frame: Up to 76 weeks
    • AddedSeverity of imAEsTime frame: Up to 76 weeks
    • AddedSeverity of IRRsTime frame: Up to 76 weeks
    • AddedOccurrence of ADAs to marlotamigTime frame: Up to 67 weeks
    • AddedMagnitude of ADAs to marlotamigTime frame: Up to 67 weeks
    • AddedOccurrence of ADAs to REGN10597Time frame: Up to 67 weeks
    • AddedMagnitude of ADAs to REGN10597Time frame: Up to 67 weeks
    • RemovedEFS rateTime frame: Up to 5 years
    • RemovedObjective response rate (ORR)Time frame: Up to 9 weeks
    • RemovedIncidence of adverse events of special interest (AESIs)Time frame: Up to 76 weeks
    • RemovedIncidence of immune-mediated adverse events (imAEs)Time frame: Up to 76 weeks
    • RemovedIncidence of ADAs to novel anti-cancer agents over timeTime frame: Up to 67 weeks
    • RemovedTiter of ADAs to novel anti-cancer agents over timeTime frame: Up to 67 weeks
    Interventions Changed REGN7075→Marlotamig. Added Drug: REGN10597. Arms added: Neoadjuvant Resectable NSCLC - Control Arm·Neoadjuvant Resectable NSCLC - Arm 1·Unresectable/Metastatic NSCLC Safety Lead-in - Arm 2·Neoadjuvant Resectable NSCLC - Arm 2; arms removed: Chemotherapy+Cemiplimab·Arm 1: Chemotherapy+Cemiplimab+REGN7075
    + 4 other changes: identifiers, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06465329
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Nov 18, 2024
Primary completion
Dec 4, 2029 (estimated)
Completion
Dec 27, 2034 (estimated)
Last update
Nov 3, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion